In prostate cancer, abrogating the expression of vimentin significantly decreases tumor cell invasiveness, an effect that has been attributed to its ability to regulate the E-cadherin/β-catenin complex via c-Src regulation [27]. The gene discussed is VIM; the disease is prostate carcinoma.